Assessment and treatment of psoriatic spondylitis

Curr Rheumatol Rep. 2009 Aug;11(4):278-83. doi: 10.1007/s11926-009-0039-8.


The axial element of psoriatic arthritis has suffered from a lack of validated outcome measures. Therefore, clinical trials demonstrating efficacy with newer therapies-such as biologic disease-modifying drugs, which for the first time have shown evidence of reduction in radiologic damage in peripheral arthritis-have focused on peripheral arthritis and rash, ignoring other outcomes. This article discusses recent advances in assessment measures and therapy recommendations borrowed from the ankylosing spondylitis literature due to the continuing absence of adequate trials examining axial involvement in the psoriatic arthritis population.

MeSH terms

  • Antirheumatic Agents / therapeutic use*
  • Arthritis, Psoriatic / complications
  • Arthritis, Psoriatic / drug therapy*
  • Back Pain / drug therapy
  • Back Pain / etiology
  • Biological Factors / therapeutic use*
  • Humans
  • Severity of Illness Index
  • Spondylitis / diagnosis
  • Spondylitis / drug therapy*
  • Spondylitis / etiology


  • Antirheumatic Agents
  • Biological Factors